Diligence memo · auto-generated · as of July 2, 2026
Editas Medicine, Inc.
Editas Medicine, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Editas Medicine, Inc. operates in Biotechnology, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Editas Medicine, Inc. has raised $120M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $120M on 2015-08-04.
Most recent recorded round closed around 2015-08-04.
Valuation (modeled)modeled
Provath models Editas Medicine, Inc. at approximately $4.9B (range $544M–$10.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.13× the median modeled value of Series D+ Biotechnology companies in 2013–2015 (7 peers) — value vs value, same stage and era. Within the normal band (113% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 10.9 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 92% of Biotechnology peers (4293 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Adaptive Biotechnologies Corp, Aerie Pharmaceuticals Inc, Ngm Biopharmaceuticals Inc, Adaptimmune Ltd, Sequenom Inc.
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.